<DOC>
	<DOCNO>NCT01753856</DOCNO>
	<brief_summary>The purpose study determine teriparatide denosumab affect bone postmenopausal woman osteoporosis 3 month treatment , determine bone biopsy sample take iliac crest ( upper part pelvis ) .</brief_summary>
	<brief_title>Effects Teriparatide Denosumab Bone Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Demeclocycline</mesh_term>
	<criteria>Ambulatory , postmenopausal woman ( vaginal bleeding least 2 year prior screen ) osteoporosis Bone mineral density ( BMD ) Tscore least 2.5 femoral neck ( FN ) , total hip ( TH ) , lumbar spine ( LS ) ( Lumbar vertebra L1L4 , least 2 evaluable vertebra ) , without atraumatic fracture menopause , OR BMD Tscore least 1.5 FN , TH , LS ( L1L4 , least 2 evaluable vertebra ) , 1 atraumatic fracture menopause ( vertebral nonvertebral ) . Nonvertebral fracture sit allow wrist , hip , pelvis , rib , humerus , clavicle , leg ( femur , tibia , fibula , exclude ankle ) Laboratory value serum calcium , parathyroid hormone ( PTH ) , alkaline phosphatase must within normal reference range Has increase risk osteosarcoma ( bone tumor ) ; include Paget 's disease bone , previous bone tumor , radiation involve skeleton Has allergy intolerance teriparatide denosumab and/or poor candidate teriparatide denosumab treatment ( investigator refer local product prescribe information ) Has history exposure DEM TET therapy 12 month prior screen know allergy DEM TET Has condition could put participant additional risk adverse event ( AE ) due bone biopsy procedure ( example , bleed disorder ) Has undergone 2 previous iliac crest bone biopsy ( 1 iliac crest ) Has 25hydroxyvitamin D concentration &lt; 10 nanogram per milliliter ( ng/mL ) Has currently active suspect ( within 1 year prior enrollment ) diseases affect bone metabolism , osteoporosis ( renal osteodystrophy , hyperthyroidism , osteomalacia , hyperparathyroidism ) Has history certain cancer within 5 year prior trial entry Current recent ( within 1 year prior enrollment ) celiac disease , inflammatory bowel disease , gastric bypass , malabsorption syndrome Has significantly impair hepatic renal function Has treatment systemic glucocorticoid dose â‰¥5 mg/day prednisone/day equivalent 6 calendar month prior screen Has take intravenous osteoporosis medication Has prior treatment bisphosphonates specific period time trial entry Has participate clinical trial study teriparatide , PTH , PTH analog , denosumab , prior current treatment teriparatide , PTH , PTH analog , denosumab</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>